Celldex Completes Phase 3 Enrollment for Barzolvolimab in Chronic Urticaria Trials

Celldex Therapeutics (NASDAQ: CLDX) has successfully completed patient enrollment for its global Phase 3 clinical program evaluating barzolvolimab. The program, focused on treating chronic spontaneous urticaria (CSU), includes two pivotal trials, EMBARQ-CSU1 and EMBARQ-CSU2. A total of 1,939 patients across 43 countries were enrolled, representing the largest clinical program ever conducted for antihistamine-refractory CSU. This milestone is significant for the biotech firm as it establishes a clear path toward top-line data results and potential regulatory filing. Barzolvolimab aims to provide a new therapeutic option for patients who do not respond to standard antihistamine treatments. Investors view this progress as a reduction in execution risk for Celldex's lead drug candidate.